Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Effects of moclobemide on sexual performance and nocturnal erections in psychogenic erectile dysfunction
Autore:
Mann, K; Pankok, J; Leissner, J; Benkert, O;
Indirizzi:
Univ Mainz, Dept Psychiat, D-55101 Mainz, Germany Univ Mainz Mainz Germany D-55101 , Dept Psychiat, D-55101 Mainz, Germany Univ Mainz, Dept Urol, D-55101 Mainz, Germany Univ Mainz Mainz Germany D-55101 ainz, Dept Urol, D-55101 Mainz, Germany
Titolo Testata:
PSYCHOPHARMACOLOGY
fascicolo: 1, volume: 156, anno: 2001,
pagine: 86 - 91
Fonte:
ISI
Lingua:
ENG
Soggetto:
A INHIBITOR MOCLOBEMIDE; REM-SLEEP SUPPRESSION; PENILE TUMESCENCE; DEPRESSED-PATIENTS; MAO-A; HEALTHY-VOLUNTEERS; HORMONAL SECRETION; MAJOR DEPRESSION; FLUOXETINE; SERTRALINE;
Keywords:
moclobemide; erectile dysfunction; nocturnal erections; sleep;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
43
Recensione:
Indirizzi per estratti:
Indirizzo: Mann, K Univ Mainz, Dept Psychiat, Untere Zahlbacher Str 8, D-55101 Mainz,Germany Univ Mainz Untere Zahlbacher Str 8 Mainz Germany D-55101 Germany
Citazione:
K. Mann et al., "Effects of moclobemide on sexual performance and nocturnal erections in psychogenic erectile dysfunction", PSYCHOPHAR, 156(1), 2001, pp. 86-91

Abstract

Rationale and objectives: We tested the hypothesis that the selective reversible MAO-A inhibitor moclobemide has a specific therapeutic effect on erectile dysfunction independent of its antidepressive properties. Methods: Ina double-blind placebo controlled study, 12 male outpatients suffering from psychogenic erectile dysfunction without any other psychiatric disorder were investigated. Based on comprehensive diagnosis before the beginning of the study, organic factors relevant for sexual function were excluded. The treatment period was 8 weeks. Half the patients received 450 mg moclobemideduring the first week, and 600 mg afterwards: the others received placebo. Apart from assessment of erectile function by means of the Clinical GlobalImpression (CGI) scale, nocturnal erections were measured under polysomnographic control at baseline and at the end of the treatment period. Results:The evaluation of the CGI scale revealed a clearly stronger improvement under moclobemide compared to placebo during the study period. The therapeutic efficacy found on the subjective level had no clear correlate on the neurophysiological level. No alterations of nocturnal erectile parameters were obvious under treatment, neither were clinically relevant alterations foundregarding sleep EEG parameters. The medication was well tolerated without serious adverse events. Conclusions: The findings support the hypothesis that moclobemide has a specific effect on erectile dysfunction. Thus, patients suffering from psychogenic erectile dysfunction who are not depressed might benefit from moclobemide without relevant side effects.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 19/01/20 alle ore 00:56:36